BioCryst Pharmaceuticals (NASDAQ:BCRX) reported Q4 2017 earnings this Morning, coming in at ($0.20) per share, missing Wall Street’s estimates of ($0.15) per Share. Revenue for the quarter came in at $3.89 million missing the streets estimates of $6.07 million Recent Insider Trading for BioCryst Pharmaceuticals (NASDAQ:BCRX)
- On 11/13/2017 William P Sheridan, CMO, sold 64,310 with an average share price of $4.72 per share and the total transaction amounting to $303,543.20.
- On 9/18/2017 Fred E Cohen, Director, sold 54,250 with an average share price of $5.42 per share and the total transaction amounting to $294,035.00.
- On 3/20/2017 Thomas R Staab II, CFO, sold 3,250 with an average share price of $9.20 per share and the total transaction amounting to $29,900.00.
- On 3/10/2017 Thomas R Staab II, Insider, sold 3,250 with an average share price of $9.06 per share and the total transaction amounting to $29,445.00.
- On 3/8/2017 Thomas R Staab II, Insider, sold 6,500 with an average share price of $8.43 per share and the total transaction amounting to $54,795.00.
- On 3/6/2017 Thomas R Staab II, Insider, sold 3,250 with an average share price of $7.90 per share and the total transaction amounting to $25,675.00.
Recent Trading for BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares of BioCryst Pharmaceuticals closed the previous trading session at 4.97 down -0.08 1.58% with 226604 shares trading hands.